Abstract
In the course of examining polymorphonuclear leukocyte (PMN) chemotaxis in patients with systemic lupus erythematosus (SLE), we have found a previously undescribed serum inhibitor of complement (C5)-derived chemotactic activity. Serum from a 25-yr-old Black female with untreated SLE, when activated with zymosan, failed completely to attract either her own or normal PMN. Incubation of normal PMN with the patient's serum did not affect their subsequent random motility or chemotactic response toward normal zymosan-treated serum (ZTS). The patient's serum, however, did inhibit the chemotactic activity of normal ZTS and of column-purified C5-derived peptide(s), but had no effect on the chemotactic activity of either the synthetic peptide, N-formylmethionyl leucyl-phenylalanine or a filtrate prepared from a culture of Escherichia coli (bacterial chemotactic factor). The inhibitory activity in the patient's serum resisted heating at 56°C for 30 min and could be separated from C5-derived chemotactic activity in the patient's ZTS (or normal ZTS that had been incubated with the patient's serum) by chromatography on Sephadex G-75. Despite its effect on C5-derived chemotactic activity, the patient's serum did not influence two other C5-derived biologic activities: PMN lysosomal enzyme-releasing activity and PMN-aggregating activity. Chromatography of the patient's serum (65% ammonium sulfate pellet) on Sephadex G-200 yielded three distinct peaks of inhibitory activity. Two were heat labile and exhibited other properties of the previously described chemotactic factor inactivators of normal human serum. The third and most active peak, however, resisted heating at 56°C for 30 min, eluted with an apparent mol wt of 50,000-60,000, and acted specifically on C5-derived chemotactic activity. This uniquely specific, heat-stable inhibitor of C5-derived chemotactic activity has been found thus far in serum from 4 of 11 patients with active SLE and may account, in part, for altered host defenses against infections caused by pyogenic microorganisms.
Full text
PDF









Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berenberg J. L., Ward P. A. Chemotactic factor inactivator in normal human serum. J Clin Invest. 1973 May;52(5):1200–1206. doi: 10.1172/JCI107287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bokisch V. A., Müller-Eberhard H. J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970 Dec;49(12):2427–2436. doi: 10.1172/JCI106462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brandt L., Hedberg H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scand J Haematol. 1969;6(5):348–353. doi: 10.1111/j.1600-0609.1969.tb02420.x. [DOI] [PubMed] [Google Scholar]
- Clark R. A., Kimball H. R., Decker J. L. Neutrophil chemotaxis in systemic lupus erythematosus. Ann Rheum Dis. 1974 Mar;33(2):167–172. doi: 10.1136/ard.33.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Craddock P. R., Hammerschmidt D., White J. G., Dalmosso A. P., Jacob H. S. Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest. 1977 Jul;60(1):260–264. doi: 10.1172/JCI108763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Craddock P. R., White J. G., Jacob H. S. Potentiation of complement (C5a)-induced granulocyte aggregation by cytochalasin B. J Lab Clin Med. 1978 Mar;91(3):490–499. [PubMed] [Google Scholar]
- Dubois E. L., Wierzchowiecki M., Cox M. B., Weiner J. M. Duration and death in systemic lupus erythematosus. An analysis of 249 cases. JAMA. 1974 Mar 25;227(12):1399–1402. [PubMed] [Google Scholar]
- Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
- Fernandez H. N., Hugli T. E. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976 Nov;117(5 Pt 1):1688–1694. [PubMed] [Google Scholar]
- Gallin J. I., Rosenthal A. S. The regulatory role of divalent cations in human granulocyte chemotaxis. Evidence for an association between calcium exchanges and microtubule assembly. J Cell Biol. 1974 Sep;62(3):594–609. doi: 10.1083/jcb.62.3.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goetzl E. J. Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty's syndrome and systemic lupus erythematosus. Ann Rheum Dis. 1976 Dec;35(6):510–515. doi: 10.1136/ard.35.6.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldstein B. D. Production of paroxysmal nocturnal haemoglobinuria-like red cells by reducing and oxidizing agents. Br J Haematol. 1974 Jan;26(1):49–58. doi: 10.1111/j.1365-2141.1974.tb00448.x. [DOI] [PubMed] [Google Scholar]
- Goldstein I. M., Brai M., Osler A. G., Weissmann G. Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. J Immunol. 1973 Jul;111(1):33–37. [PubMed] [Google Scholar]
- Goldstein I. M., Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol. 1974 Nov;113(5):1583–1588. [PubMed] [Google Scholar]
- Goldstein I., Hoffstein S., Gallin J., Weissmann G. Mechanisms of lysosomal enzyme release from human leukocytes: microtubule assembly and membrane fusion induced by a component of complement. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2916–2920. doi: 10.1073/pnas.70.10.2916. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jasin H. E., Orozco J. H., Ziff M. Serum heat-labile opsonins in systemic lupus erythematosus. J Clin Invest. 1974 Feb;53(2):343–353. doi: 10.1172/JCI107566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Keller H. U., Hess M. W., Cottier H. The chemokinetic effect of serum albumin. Experientia. 1977 Oct 15;33(10):1386–1387. doi: 10.1007/BF01920196. [DOI] [PubMed] [Google Scholar]
- LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
- Landry M. Phagocyte function and cell-mediated immunity in systemic lupus erythematosus. Arch Dermatol. 1977 Feb;113(2):147–154. [PubMed] [Google Scholar]
- Lee P., Urowitz M. B., Bookman A. A., Koehler B. E., Smythe H. A., Gordon D. A., Ogryzlo M. A. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med. 1977 Jan;46(181):1–32. [PubMed] [Google Scholar]
- Maderazo D. G., Ward P. A., Woronick C. L., Quintiliani R. Partial characterization of a cell-directed inhibitor of leukotaxis in human serum. J Lab Clin Med. 1977 Jan;89(1):190–199. [PubMed] [Google Scholar]
- Maderazo E. C., Ward P. A., Quintiliani R. Defective regulation of chemotaxis in cirrhosis. J Lab Clin Med. 1975 Apr;85(4):621–630. [PubMed] [Google Scholar]
- Maderazo E. G., Ward P. A., Woronick C. L., Kubik J., DeGraff A. C., Jr Leukotactic dystunction in sarcoidosis. Ann Intern Med. 1976 Apr;84(4):414–419. doi: 10.7326/0003-4819-84-4-414. [DOI] [PubMed] [Google Scholar]
- Minta J. O., Man D. P. Cleavage of human C5 by trypsin: characterization of the digestion products by gel electrophoresis. J Immunol. 1977 Nov;119(5):1597–1602. [PubMed] [Google Scholar]
- Nilsson U. R., Mandle R. J., Jr, McConnell-Mapes J. A. Human C3 and C5: subunit structure and modifications by trypsin and C42-C423. J Immunol. 1975 Feb;114(2 Pt 2):815–822. [PubMed] [Google Scholar]
- Schiffmann E., Corcoran B. A., Wahl S. M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059–1062. doi: 10.1073/pnas.72.3.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Showell H. J., Freer R. J., Zigmond S. H., Schiffmann E., Aswanikumar S., Corcoran B., Becker E. L. The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils. J Exp Med. 1976 May 1;143(5):1154–1169. doi: 10.1084/jem.143.5.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith C. W., Hollers J. C., Dupree E., Goldman A. S., Lord R. A. A serum inhibitor of leukotaxis in a child with recurrent infections. J Lab Clin Med. 1972 Jun;79(6):878–885. [PubMed] [Google Scholar]
- Snyderman R., Phillips J. K., Mergenhagen S. E. Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates. J Exp Med. 1971 Nov 1;134(5):1131–1143. doi: 10.1084/jem.134.5.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Staples P. J., Gerding D. N., Decker J. L., Gordon R. S., Jr Incidence of infection in systemic lupus erythematosus. Arthritis Rheum. 1974 Jan-Feb;17(1):1–10. doi: 10.1002/art.1780170102. [DOI] [PubMed] [Google Scholar]
- Stossel T. P. Phagocytosis: recognition and ingestion. Semin Hematol. 1975 Jan;12(1):83–116. [PubMed] [Google Scholar]
- Till G., Ward P. A. Two distinct chemotactic factor inactivators in human serum. J Immunol. 1975 Feb;114(2 Pt 2):843–847. [PubMed] [Google Scholar]
- ULMER D. D., VALLEE B. L., WACKER W. E. Metalloenzymes and myocardial infarction. II. Malic and lactic dehydrogenase activities and zinc concentrations in serum. N Engl J Med. 1956 Sep 6;255(10):450–456. doi: 10.1056/NEJM195609062551001. [DOI] [PubMed] [Google Scholar]
- Urowitz M. B., Bookman A. A., Koehler B. E., Gordon D. A., Smythe H. A., Ogryzlo M. A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb;60(2):221–225. doi: 10.1016/0002-9343(76)90431-9. [DOI] [PubMed] [Google Scholar]
- Van Epps D. E., Williams R. C., Jr Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976 Nov 2;144(5):1227–1242. doi: 10.1084/jem.144.5.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
- Ward P. A., Goralnick S., Bullock W. E. Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med. 1976 Jun;87(6):1025–1032. [PubMed] [Google Scholar]
- Ward P. A., Lepow I. H., Newman L. J. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol. 1968 Apr;52(4):725–736. [PMC free article] [PubMed] [Google Scholar]
- Ward P. A., Ozols J. Characterization of the protease activity in the chemotactic factor inactivator. J Clin Invest. 1976 Jul;58(1):123–129. doi: 10.1172/JCI108440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wissler J. H., Stecher V. J., Sorkin E. Biochemistry and biology of a leucotactic binary serum peptide system related to anaphylatoxin. Int Arch Allergy Appl Immunol. 1972;42(5):722–747. doi: 10.1159/000230652. [DOI] [PubMed] [Google Scholar]
- Zigmond S. H., Hirsch J. G. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973 Feb 1;137(2):387–410. doi: 10.1084/jem.137.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zurier R. B. Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus. Arthritis Rheum. 1976 Jan-Feb;19(1):73–78. doi: 10.1002/art.1780190112. [DOI] [PubMed] [Google Scholar]